Gastrooesophageal Cancer
12
1
3
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
25.0%
3 terminated out of 12 trials
50.0%
-36.5% vs benchmark
25%
3 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
Permission to Collect Blood Over Time for Research
Esophageal Stump Washout
B-Receptor Signaling in Cardiomyopathy